Moderna, Merck begin late-stage study for mRNA cancer therapy

Moderna (MRNA.O) and Merck & Co (MRK.N) said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.